Arcutis BiotherapeuticsvsUnitedHealth

ARQT and UNH stock compared: price, dividend, valuation and results, from SEC filings.

ARQT

Arcutis Biotherapeutics, Inc.

$27.17

Value $3.4B

+1.02%
ARQT's page

UNH

UnitedHealth Group Incorporated

$330.48

Value $300B

-10.21%
UNH's page

Arcutis Biotherapeutics (ARQT) has a market value of $3.4B and UnitedHealth (UNH) $300B. Over the last year, with dividends, ARQT moved +5.5% and UNH +12.1%. The P/E is 112.7 for ARQT and 18.9 for UNH. Dividend yield: ARQT none, UNH 2.74%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ARQT$3.4B

    UNH$300B

    UNH is 89 times ARQT

  • Revenue, 12 months

    ARQT$509M

    UNH$450B

    UNH is 884 times ARQT

  • Net income, 12 months

    ARQT$30M

    UNH$15.9B

    UNH is 531 times ARQT

  • Operating margin

    ARQT6.9%

    UNH5.3%

    1.6 points apart

  • ROIC

    ARQT9.0%

    UNH11.3%

    2.3 points apart

  • P/E

    ARQT112.7

    UNH18.9

    ARQT is 6.0 times UNH

  • Dividend yield

    ARQT0.0%

    UNH2.7%

    2.7 points apart

  • 5-year return

    ARQT+42.5%

    UNH-14.7%

    57.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ARQT+42.5%

UNH-14.7%

5010015020222023202420252026
Returns by period
PeriodARQTWith dividendsUNHWith dividends
1 year since November 17, 2025+5.5%Price +5.5%+12.1%Price +9.2%
3 years since November 17, 2023+1,253.4%+138.3% a yearPrice +1,253.4%-30.5%-11.4% a yearPrice -34.8%
5 years since November 17, 2021+42.5%+7.3% a yearPrice +42.5%-14.7%-3.1% a yearPrice -22.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ARQTArcutis BiotherapeuticsUNHUnitedHealth

Valuation

ARQTUNH
Valuation
Price$27.17$330.48
Market value$3.4B$300B
Enterprise value (EV)–$346B
P/E112.718.9
P/E, 5-year median–25.0
P/B13.82.9
EV/EBIT–14.5
Free cash flow yield1.8%7.6%

Results and growth

ARQTUNH
Results and growth
Revenue, 12 months$509M$450B
Net income, 12 months$30M$15.9B
Free cash flow, 12 months$60M$22.8B
Earnings per share, 12 months$0.24$17.52
Revenue growth, year on year91.3%11.8%
Revenue growth a year, past–+11.7%over 5 years
EPS growth a year, past–-3.8%over 5 years

Margins and returns on capital

ARQTUNH
Margins and returns on capital
Gross margin91.2%88.3%
Operating margin6.9%5.3%
Net margin5.9%3.5%
ROIC9.0%11.3%
ROE14.9%15.5%

Balance sheet

ARQTUNH
Balance sheet
Cash$259M$28.5B
Total debt–$74.3B
Net debt / EBITDA–1.6
Interest cover2.6×6.2×

Dividends and buybacks

ARQTUNH
Dividends and buybacks
Dividend yield–2.7%
Dividend per share, 12 months–$9.06
Dividend growth a year, past–+12.6%over 5 years
Buyback yield–1.8%
Shareholder yield–4.6%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ARQT or UNH

Didn't find what you were looking for?

Ask us
Which is bigger, Arcutis Biotherapeutics or UnitedHealth?

By market value, UnitedHealth ($300B) is about 89.0 times Arcutis Biotherapeutics ($3.4B), at today's prices.

How did ARQT and UNH stock do over the last 5 years?

Since November 17, 2021, ARQT's price moved +42.5% and UNH's -22.1%. With dividends: ARQT +42.5% (+7.3% a year), UNH -14.7% (-3.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, ARQT or UNH?

The dividend yield at today's price is none for Arcutis Biotherapeutics and 2.74% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.

What is the P/E of ARQT and UNH?

At today's price, the P/E is 112.7 for ARQT and 18.9 for UNH. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Arcutis Biotherapeutics or UnitedHealth?

Over the last twelve months, the net margin was 5.9% for Arcutis Biotherapeutics and 3.5% for UnitedHealth, and the operating margin 6.9% and 5.3%. Revenue was $509M and $450B.

Which is the better investment, Arcutis Biotherapeutics or UnitedHealth?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.